Nusayba Ali Bagegni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nusayba Ali Bagegni has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Foluso Olabisi Ademuyiwa
Department of Medicine, Washington University in St Louis, St Louis, Mo
46 shared publications - Andrew A. Davis
Division of Oncology, Washington University in St. Louis, St. Louis, MO, United States
45 shared publications - Cynthia X. Ma
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, USA
45 shared publications - Katherine Clifton
Division of Oncology, Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, USA
45 shared publications - Ron Bose
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, USA
45 shared publications - Aditya Bardia
University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, USA
41 shared publications
Latest Publications
- 20 October 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44  (30) , 2919-2928
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR
PURPOSE: EA1181 (ClinicalTrials.gov identifier: NCT04266249 ) is a single-arm trial evaluating neoadjuvant taxane, trastuzumab, and pertuzumab (THP) in patients with clinical stage II/IIIa human epidermal growth factor receptor 2 (HER2)–positive breast cancer. This report focuses on the secondary end points of pathologic complete response (pCR) rates and associated factors. The primary end point—3-year recurrence-free survival among patients achieving a pCR (ypT0/Tis, ypN0)—will be reported when data mature. Methods: Patients received four cycles of trastuzumab and pertuzumab (HP) with either once per week paclitaxel (12 weeks) or docetaxel (every 3 weeks for four cycles), followed by surgery. Clinicopathologic characteristics were assessed in all patients. The HER2DX pCR score was determined using diagnostic biopsy samples in a representative subset. Logistic regression models identified factors associated with pCR. RESULTS: A total of 2,175 patients were enrolled (781 HER2+/estrogen receptor‑negative [ER–]; 1,394 HER2+/ER+). Of 2,141 patients who initiated THP, the overall pCR rate was 43.8%: 63.7% in HER2+/ER– and 32.4% in HER2+/ER+ tumors. Higher pCR rates were observed in tumors that were ER-negative or low ER expressing, progesterone receptor-negative or low expressing, HER2 immunohistochemistry (IHC) 3+, and in patients treated with once per week paclitaxel. T3 disease was associated with a lower pCR rate in HER2+/ER– tumors; otherwise, tumor (T) and nodal (N) stage did not significantly affect pCR. Among 569 patients assessed for HER2DX pCR scores, a high score was independently associated with higher pCR rates, after adjustment for clinicopathologic variables. CONCLUSION: Neoadjuvant THP achieved pCR in nearly two-thirds of patients with HER2+/ER– and one third with HER2+/ER+ breast cancer. Low hormone receptor expression, HER2 IHC 3+ status, once per week paclitaxel use, and a high HER2DX pCR score were independent predictors of pCR. These findings should help optimize risk stratification and treatment personalization for patients with HER2-positive breast cancer.
- 20 October 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44  (30) , 2919-2928
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR
PURPOSE: EA1181 (ClinicalTrials.gov identifier: NCT04266249 ) is a single-arm trial evaluating neoadjuvant taxane, trastuzumab, and pertuzumab (THP) in patients with clinical stage II/IIIa human epidermal growth factor receptor 2 (HER2)–positive breast cancer. This report focuses on the secondary end points of pathologic complete response (pCR) rates and associated factors. The primary end point—3-year recurrence-free survival among patients achieving a pCR (ypT0/Tis, ypN0)—will be reported when data mature. Methods: Patients received four cycles of trastuzumab and pertuzumab (HP) with either once per week paclitaxel (12 weeks) or docetaxel (every 3 weeks for four cycles), followed by surgery. Clinicopathologic characteristics were assessed in all patients. The HER2DX pCR score was determined using diagnostic biopsy samples in a representative subset. Logistic regression models identified factors associated with pCR. RESULTS: A total of 2,175 patients were enrolled (781 HER2+/estrogen receptor‑negative [ER–]; 1,394 HER2+/ER+). Of 2,141 patients who initiated THP, the overall pCR rate was 43.8%: 63.7% in HER2+/ER– and 32.4% in HER2+/ER+ tumors. Higher pCR rates were observed in tumors that were ER-negative or low ER expressing, progesterone receptor-negative or low expressing, HER2 immunohistochemistry (IHC) 3+, and in patients treated with once per week paclitaxel. T3 disease was associated with a lower pCR rate in HER2+/ER– tumors; otherwise, tumor (T) and nodal (N) stage did not significantly affect pCR. Among 569 patients assessed for HER2DX pCR scores, a high score was independently associated with higher pCR rates, after adjustment for clinicopathologic variables. CONCLUSION: Neoadjuvant THP achieved pCR in nearly two-thirds of patients with HER2+/ER– and one third with HER2+/ER+ breast cancer. Low hormone receptor expression, HER2 IHC 3+ status, once per week paclitaxel use, and a high HER2DX pCR score were independent predictors of pCR. These findings should help optimize risk stratification and treatment personalization for patients with HER2-positive breast cancer.
- Open Access
Patient perspectives on cardioprotective medication during breast cancer treatment
Background: Cardiotoxicity remains a key concern of HER2-directed therapies, with no proven prevention strategies. The success of cardioprotective interventions will depend not only on efficacy, but on patient acceptability, an underexplored determinant of trial participation and clinical implementation. Objectives: To evaluate willingness to take cardioprotective medication and identify factors influencing decision-making among individuals with HER2-positive breast cancer. Methods: We conducted a cross-sectional online survey of adults with HER2-positive breast cancer in Australia and the United States. The survey assessed willingness, beliefs regarding benefits and risks, and treatment preferences. Multivariable logistic regression examined associations between clinical and demographic characteristics and willingness. Results: Among 74 respondents (Australia n=24; United States n=50), 74.3% reported being likely or very likely to take cardioprotective medication. Physician recommendation emerged as a dominant driver (79.1%). While most participants valued long-term cardiovascular health (72.9%), uncertainty regarding benefit was common (60.4%). Cancer-related outcomes were prioritized over cardiovascular outcomes. Participants demonstrated flexibility regarding treatment burden, including willingness to take multiple medications and continue therapy long-term. No demographic or clinical predictors of willingness were identified. Perceived acceptability, appropriateness, and feasibility were consistently high. Conclusions: Willingness to adopt cardioprotective strategies is high but conditional, shaped by cancer priorities, clinician endorsement, and uncertainty regarding benefit. These findings highlight patient acceptability as a critical, and often overlooked, determinant of successful trial participation and downstream clinical implementation in cardio-oncology.
Open AccessPatient perspectives on cardioprotective medication during breast cancer treatment
Background: Cardiotoxicity remains a key concern of HER2-directed therapies, with no proven prevention strategies. The success of cardioprotective interventions will depend not only on efficacy, but on patient acceptability, an underexplored determinant of trial participation and clinical implementation. Objectives: To evaluate willingness to take cardioprotective medication and identify factors influencing decision-making among individuals with HER2-positive breast cancer. Methods: We conducted a cross-sectional online survey of adults with HER2-positive breast cancer in Australia and the United States. The survey assessed willingness, beliefs regarding benefits and risks, and treatment preferences. Multivariable logistic regression examined associations between clinical and demographic characteristics and willingness. Results: Among 74 respondents (Australia n=24; United States n=50), 74.3% reported being likely or very likely to take cardioprotective medication. Physician recommendation emerged as a dominant driver (79.1%). While most participants valued long-term cardiovascular health (72.9%), uncertainty regarding benefit was common (60.4%). Cancer-related outcomes were prioritized over cardiovascular outcomes. Participants demonstrated flexibility regarding treatment burden, including willingness to take multiple medications and continue therapy long-term. No demographic or clinical predictors of willingness were identified. Perceived acceptability, appropriateness, and feasibility were consistently high. Conclusions: Willingness to adopt cardioprotective strategies is high but conditional, shaped by cancer priorities, clinician endorsement, and uncertainty regarding benefit. These findings highlight patient acceptability as a critical, and often overlooked, determinant of successful trial participation and downstream clinical implementation in cardio-oncology.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplemental Figure 3. Interaction between HER2-positive status and oncogenic pathways on overall survival.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplemental Figure 3. Interaction between HER2-positive status and oncogenic pathways on overall survival.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
HER2 subtype and genomic alterations for all patients
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
HER2 subtype and genomic alterations for all patients
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplemental Figure 1. Mutation distribution for the PIK3CA gene in the overall study population divided by HER2 status.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplemental Figure 1. Mutation distribution for the PIK3CA gene in the overall study population divided by HER2 status.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplemental Figure 2. Interaction between HER2-low status and oncogenic pathways on overall survival.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplemental Figure 2. Interaction between HER2-low status and oncogenic pathways on overall survival.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Purpose:About 50% of breast cancers are defined as HER2-low and may benefit from HER2-directed antibody–drug conjugates. While tissue sequencing has evaluated potential differences in genomic profiles for patients with HER2-low breast cancer, genetic alterations in circulating tumor DNA (ctDNA) have not been well described.Experimental Design:We retrospectively analyzed 749 patients with metastatic breast cancer (MBC) and ctDNA evaluation by Guardant360 from three academic medical centers. Tumors were classified as HER2-low, HER2-0 (IHC 0) or HER2-positive. Single-nucleotide variants, copy-number variants, and oncogenic pathways were compared across the spectrum of HER2 expression. Overall survival (OS) was evaluated by HER2 status and according to oncogenic pathways.Results:Patients with HER2-low had higher rates of PIK3CA mutations [relative risk ratio (RRR), 1.57; P = 0.024] compared with HER2-0 MBC. There were no differences in ERBB2 alterations or oncogenic pathways between HER2-low and HER2-0 MBC. Patients with HER2-positive MBC had more ERBB2 alterations (RRR, 12.43; P = 0.002 for amplification; RRR, 3.22; P = 0.047 for mutations, in the hormone receptor–positive cohort), fewer ERS1 mutations (RRR, 0.458; P = 0.029), and fewer ER pathway alterations (RRR, 0.321; P < 0.001). There was no difference in OS for HER2-low and HER2-0 MBC [HR, 1.01; 95% confidence interval (CI), 0.79–1.29], while OS was improved in HER2-positive MBC (HR, 0.32; 95% CI, 0.21–0.49; P < 0.001).Conclusions:We observed a higher rate of PIK3CA mutations, but no significant difference in ERBB2 alterations, oncogenic pathways, or prognosis, between patients with HER2-low and HER2-0 MBC. If validated, our findings support the conclusion that HER2-low MBC does not represent a unique biological subtype.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Purpose:About 50% of breast cancers are defined as HER2-low and may benefit from HER2-directed antibody–drug conjugates. While tissue sequencing has evaluated potential differences in genomic profiles for patients with HER2-low breast cancer, genetic alterations in circulating tumor DNA (ctDNA) have not been well described.Experimental Design:We retrospectively analyzed 749 patients with metastatic breast cancer (MBC) and ctDNA evaluation by Guardant360 from three academic medical centers. Tumors were classified as HER2-low, HER2-0 (IHC 0) or HER2-positive. Single-nucleotide variants, copy-number variants, and oncogenic pathways were compared across the spectrum of HER2 expression. Overall survival (OS) was evaluated by HER2 status and according to oncogenic pathways.Results:Patients with HER2-low had higher rates of PIK3CA mutations [relative risk ratio (RRR), 1.57; P = 0.024] compared with HER2-0 MBC. There were no differences in ERBB2 alterations or oncogenic pathways between HER2-low and HER2-0 MBC. Patients with HER2-positive MBC had more ERBB2 alterations (RRR, 12.43; P = 0.002 for amplification; RRR, 3.22; P = 0.047 for mutations, in the hormone receptor–positive cohort), fewer ERS1 mutations (RRR, 0.458; P = 0.029), and fewer ER pathway alterations (RRR, 0.321; P < 0.001). There was no difference in OS for HER2-low and HER2-0 MBC [HR, 1.01; 95% confidence interval (CI), 0.79–1.29], while OS was improved in HER2-positive MBC (HR, 0.32; 95% CI, 0.21–0.49; P < 0.001).Conclusions:We observed a higher rate of PIK3CA mutations, but no significant difference in ERBB2 alterations, oncogenic pathways, or prognosis, between patients with HER2-low and HER2-0 MBC. If validated, our findings support the conclusion that HER2-low MBC does not represent a unique biological subtype.